BRCA1/2 in pancreatic cancer

1 EU-approved indication in pancreatic cancer needs a BRCA1/2 result: olaparib (maintenance, metastatic).

Line of therapy

Approved indications, Pancreatic cancer
DrugBiomarker requirementRegimenSettingConditions
BRCA1/2 mutation1
Olaparib
Lynparza
Germline BRCA1/2 mutation
Monotherapy
Maint.
metastatic
After minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen without progression

One approval for Pancreatic needs no biomarker and applies whatever the result. All approvals for Pancreatic

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Olaparib (Lynparza)
    monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.